Italfarmaco Spa

Tiziano Oldoni

Paolo Mascagni

Marco Adami

Roberta Artico

Alessandro Rambaldi

Tiziano Barbui

Daniele Barbareschi

Jaime Moscoso

Method of treating Philadelphia-negative myeloproliferative syndromes in a patient suffering from such syndromes. The method is carried out by administering to the patient diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl -methyl]-ammonium chloride, or other pharmaceutically acceptable salts and/or solvates, in a daily dosage amount of from 10 to 150 mg per patient.

Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes

Physically and chemically stable aqueous oral suspensions of riluzole and manufacturing methods thereof. The suspensions contain riluzole in particle form and at least a wetting agent, preferably a surfactant. Riluzole is present in amounts from about 0.1% to about 20% w/v and has an average particle size lower than 200 &#x3bc;m. The suspensions are devoid of the known local (mouth) anaesthetic effects of riluzole.

Riluzole aqueous suspensions

Growing community of inventors

Rho, Italy

Tiziano Oldoni